This paper addresses the important and evolving area of peer review in radiation oncology, and provides a broad regional overview of activities across a large geographic region (Ontario, Canada) . While the paper can not comment on the value of peer review on outcomes, it does provide a snap shot of activities that allow for benchmarking. I do not have any general remarks on the paper and think it is fundamentally a sound and straightforward paper. The only general comments I would make is the methodology as to who the potential respondents that were surveyed were identified is a bit unclear. The other issue in terms of limitations is that these findings in now way inform us about the value of such peer-review activities, and this should be acknowledged in the discussion. Similarly the authors should make it clear that the results reflect perceptions of what is happening, rather than what is actually happening (at least I believe that is the case, as it is not clear whether any of the centres actually measured these findings). Ie for figure 2, the percentages of plans reviewed at each centre. Were these measured values, or just the respondents guesses about the percentages of plans reviewed? Specific comments: Abstract, page 2, line 27: "…improvements in planning processes were the highest rated benefits of peer-review…". It would be more accurate to say ""…improvements in planning processes were the highest rated perceived benefits of peer-review…", since there is no actual measure of benefits in this study.
Methods, page6, line 44. Here the survey was described as being administered by email. But I would like to see more details as to whom it was emailed. Were this department heads of each department? To whom were the department heads allowed to delegate the responses? Were there multiple potential respondents from each centre, ie sometimes the head of radiation therapy responds, sometimes head of physics etc?
Results, page 8, line 43. The reference to "at least site" is a bit vague, is this at least one of the aforementioned sites in the previous line (ie one of breast, lung or prostate), or do they mean at least one of any cancer site? Discussion, page 11, line 19. Were the authors state that some for of peer-review occurs at all centres, it would be important to add here that in no centre was it performed comprehensively on all cases. Discussion, page 12, line 27. I find the term white paper here a bit colloquial. Can the authors be more specific about what this astro paper is specifically on, is there a title for the pending paper?
Discussions page 12, line 53. it is my understanding that the are some processes of peer-review that are protected against legal submission in the event of a legal proceeding if they are kept separate from the chart. Could the authors comment on the legal framework for such processes in Ontario. This would help clarify to what extent such processes should or should not be incorporated into the medical record for example. the authors comment on who, if anyone, pays for this activity and if so how. Is there additional block funding, is it fee for services, if so, for what elements. Figure 3 . This is confusing as to the scale. Why is it only up to 11 as a maximum. Did only 11 centres respond. Was it the same 11 centres. Or did some centre to specific questions, and the total of responding centres just happens to total to 11 in the majority. In any event, clarify the total number of responding centres to any of the lung questions. 
THE STUDY
As this is not a report of a randomized trial, the CONSORT checklist is of limited value.
GENERAL COMMENTS
Generally informational. Suggested additional considerations: 1. A more basic view might also be considered, such as judging compliance of overall treatment with published guidelines, by asking a question such as "Is the management compliant with the guidelines published by NCCN, ASTRO, or ACR?" This would eliminate a favorable review of a patient whose treatment was expertly designed, contoured, and executed but for whom the therapy overall might have been inappropriate. 2. The survey appears not to have asked any question regarding patients seen in referral for whom no radiation was recommended. The omission of untreated patients being reviewed would not catch patients who were inappropriately declined for radiation when it was indicated. 3. More emphasis is suggested on the closure of the loop, in addressing what happens to the peer review information once forwarded to the attending radiation oncologist. Is there any trending? Has the physician's behavior been modified in a given case, or in subsequent similar cases? 4. A reference to ASTRO appears in the manuscript, yet the reference is to ASCO in the "2. Key Messages" paragraph, which is not mentioned in the manuscript. This is an inconsistency.
VERSION 1 -AUTHOR RESPONSE
Reviewer: Scott Tyldesley Radiation Oncologist Vancouver Centre BC Cancer Agency Canada
General comments:
This paper addresses the important and evolving area of peer review in radiation oncology, and provides a broad regional overview of activities across a large geographic region (Ontario, Canada). While the paper can not comment on the value of peer review on outcomes, it does provide a snap shot of activities that allow for benchmarking. I do not have any general remarks on the paper and think it is fundamentally a sound and straightforward paper. The only general comments I would make is the methodology as to who the potential respondents that were surveyed were identified is a bit unclear. The other issue in terms of limitations is that these findings in now way inform us about the value of such peer-review activities, and this should be acknowledged in the discussion. Similarly the authors should make it clear that the results reflect perceptions of what is happening, rather than what is actually happening (at least I believe that is the case, as it is not clear whether any of the centres actually measured these findings). Ie for figure 2, the percentages of plans reviewed at each centre. Were these measured values, or just the respondents guesses about the percentages of plans reviewed? Figure 3 . This is confusing as to the scale. Why is it only up to 11 as a maximum. Did only 11 centres respond. Was it the same 11 centres. Or did some centre to specific questions, and the total of responding centres just happens to total to 11 in the majority. In any event, clarify the total number of responding centres to any of the lung questions.
Author's Response: We agree that this was unclear, and have added to the results section that only 11 centres had peer-review processes for lung cancer and could respond to this question (p. 9) Figure 5 . Please define all abbreviations used in the footnote of the figure legend.
Author's Response: The key for abbreviations has been added to the figure legend (also added for Figure 3 ). Figure 3 , is considered within scope of peer review by some centres, but also as the domain of tumour boards by others. We have added text with regard to this important point briefly on page 10.
2. The survey appears not to have asked any question regarding patients seen in referral for whom no radiation was recommended. The omission of untreated patients being reviewed would not catch patients who were inappropriately declined for radiation when it was indicated.
Author's response: Your point is an interesting one. Traditionally, peer-review processes in Ontario have focused on appropriate delivery of RT in treated patients so that is what was focussed on in this survey of current practice. Again, the quality of decision making to not employ radiotherapy is considered by us to be a programmatic issue beyond the scope of this survey.
3. More emphasis is suggested on the closure of the loop, in addressing what happens to the peer review information once forwarded to the attending radiation oncologist. Is there any trending? Has the physician's behavior been modified in a given case, or in subsequent similar cases?
